This clinical trial is focused on studying a type of lung cancer known as non-small cell lung cancer that has a specific mutation called KRAS G12C. The study is comparing the effectiveness and safety of a new medication, referred to as JDQ443, with an existing treatment called docetaxel. Participants in the study have previously received treatment for their cancer, which is either locally advanced or has spread to other parts of the body.

The purpose of the study is to see how well JDQ443 works compared to docetaxel in controlling the cancer. Participants will receive either JDQ443 in tablet form or docetaxel through an intravenous infusion, which means it is given directly into a vein. Some participants may also receive a placebo, which looks like the real medication but does not contain any active ingredients. The study will monitor how long the cancer stays under control and will also look at overall survival rates, which means how long participants live after starting the treatment.

Throughout the study, participants will have regular check-ups to monitor their health and any side effects they might experience. The study will also collect information on how the treatments affect symptoms like chest pain, coughing, and shortness of breath. The trial is expected to continue until the end of 2025, and the results will help determine if JDQ443 is a better option for treating this type of lung cancer compared to the current standard treatment with docetaxel.